Immune Persistence and Safety After SARS-CoV-2 BNT162b1 mRNA Vaccination in Chinese Adults: A Randomized, Placebo-Controlled, Double-Blind Phase 1 Trial

INTRODUCTION: BNT162b1 is a lipid nanoparticle-formulated, nucleoside-modified mRNA SARS-CoV-2 vaccine. Here, we report safety and immune persistence data following a primary two-dose vaccination schedule administered 21 days apart. METHODS: Immune persistence was determined at month 3 in 72 younger...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Jingxin, Hui, Ai-Min, Zhang, Xiang, Ge, Lei, Qiu, Yuanzheng, Tang, Rong, Ye, Huayue, Wang, Xiyuan, Lin, Mei, Zhu, Zhongkui, Zheng, Jianfei, Qiu, Jingjun, Lagkadinou, Eleni, Shpyro, Svetlana, Ozhelvaci, Orkun, Türeci, Özlem, Khondker, Zakaria, Yin, Wanrong, Shishkova, Yoana, Jia, Siyue, Pan, Hongxing, Peng, Fuzhong, Ma, Zhilong, Wu, Zhenggang, Guo, Xiling, Shi, Yunfeng, Muik, Alexander, Şahin, Uğur, Zhu, Li, Zhu, Fengcai
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Healthcare 2022
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9245386/
https://www.ncbi.nlm.nih.gov/pubmed/35771353
http://dx.doi.org/10.1007/s12325-022-02206-1

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9245386/
https://www.ncbi.nlm.nih.gov/pubmed/35771353
http://dx.doi.org/10.1007/s12325-022-02206-1

Ejemplares similares